Pelvic Chronic Pain Syndrome (PCPS) represents a significant clinical challenge, characterized by persistent pelvic pain in the absence of identifiable pathology. This condition, potentially stemming from musculoskeletal, neurologic, or psychosocial factors, impacts patient quality of life. SoftWave Therapy provides a non-invasive therapeutic option by:
Erectile Dysfunction (ED) is a multifactorial condition, affecting men’s health and well-being. With vascular, neurogenic, hormonal, and psychogenic factors at play, ED requires a multifaceted treatment approach. SoftWave Therapy emerges as an innovative aid, offering:
Peyronie Disease, marked by fibrous scar tissue formation leading to penile curvature and pain, presents unique treatment challenges. Beyond the physical discomfort, it can significantly affect psychological well-being. SoftWave Therapy offers a novel therapeutic avenue by:
Persistent Genital Arousal Disorder (PGAD) and related sexual health concerns in women often lack adequate recognition and treatment. These conditions, resulting from an interplay of neurovascular and psychological factors, can lead to significant distress. SoftWave Therapy introduces a respectful and efficacious treatment modality by:
Elevate your practice to the forefront of medical innovation and achieve superior patient results with maximum ROI
SoftWave Therapy is not only a preferred choice among private healthcare providers but also a recognized option for government medical facilities, having secured a General Services Administration (GSA) contract
SoftWave’s patented broad-focused shockwave therapy devices are FDA-cleared and effective at treating a variety of soft tissue injuries and conditions.
Low-Intensity Shockwave Therapy (Li-ESWT) is an evidence-based approach to improving patient outcomes.
Alison N. Schroeder, MD; Adam S. Tonforde, MD
Alison N. Schroeder, MD; Adam S. Tonforde, MD
Alison N. Schroeder, MD; Adam S. Tonforde, MD
Alison N. Schroeder, MD; Adam S. Tonforde, MD
